Gene translocations that repress the function of the Runx1 transcription factor play a critical role in the development of myeloid leukemia. In this report, we demonstrate that Runx1 precisely regulates c-fms (CSF-1 receptor) gene expression. Runx1 controlled expression by binding to multiple sites within the mouse c-fms gene, allowing interaction between promoter and downstream enhancer elements. The runx1 and c-fms genes showed an identical pattern of expression in mature macrophages. Runx1 expression was repressed in CSF-1 stimulated, proliferating bone marrow-derived macrophages (BMM) and significantly increased in quiescent, CSF-1 starved cells. The RAW264.7 and Mono-Mac-6, macrophage-like cell lines expressed low levels of Runx1 and both showed growth arrest and cell death with ectopic expression of Runx1. The EM-3 cell line, which represents an early myeloid progenitor cell line, showed growth arrest with Runx1 expression in the absence of any detectable changes in cell differentiation. These findings suggest that Runx1 regulates growth and survival of myeloid cells and provide a novel insight into the role of Runx family gene translocations in leukemogenesis.
Introduction
The AML-1/Runx1 transcription factor is a common target of gene translocation in leukemia (Maruyama et al., 1993; Heibert et al., 2001) . The DNA-binding activity of this protein was originally characterized as core binding factor (CBF) based upon the ability to bind the core enhancer sequence of the Moloney Leukemia Virus LTR. CBF was subsequently found to comprise a complex of Runx1 and a non-DNA-binding subunit, CBFb (Wang and Speck, 1992) . Runx1 and CBFb are normally expressed in all hematopoietic tissues, during myeloid differentiation and in mature macrophages (Tracey and Speck, 2000) . Runx1 has been shown to be involved in expression of numerous tissue-specific genes and can cooperatively activate transcription in concert with tissue-specific transcription factors such as C/EBPa, PU.1 and c-Myb (Zhang et al., 1996a, b; Lutterbach and Hiebert, 2000) . The importance of Runx1 and CBFb in normal and malignant hematopoiesis is evident from frequent translocations in both genes in leukemia and a complete loss of fetal hematopoiesis by targeted disruption of either gene (Miyoshi et al., 1993; Okuda et al., 1996; Sasaki et al., 1996; Wang et al., 1996) .
Translocations in CBF genes result in fusion proteins that act as dominant inhibitors of native CBF function. The t(8;21) translocation fuses nearly all of the transcriptional repressor ETO to the N-terminus of Runx1, resulting in replacement of the C-terminal transactivation domain of Runx1 with the histone deacetylase domain of ETO (Runx1-ETO) (Downing et al., 1993; Meyers et al., 1995) . The inv(16) translocation fuses MYH11, a smooth muscle myosin heavy chain gene, to CBFb(CBFb-SMMC). The resulting fusion protein interferes with nuclear localization of the CBF protein complex (Thompson et al., 1991; Adya et al., 1998) . Ectopic expression in transgenic mice showed that although these fusion proteins can disrupt normal hematopoiesis, they are not sufficient for the development of leukemia (Castilla et al., 1999; Heibert et al., 2001) .
The link between loss of CBF function and leukemia suggests that CBF proteins act as strong tumor suppressors. Many genes that reside at breakpoint regions in leukemogenic translocations and numerous tumor suppressor genes are important regulators of cell proliferation and survival. Loss of Runx1 function was believed to impact primarily on cell differentiation resulting in abnormal accumulation of progenitor cells. A recent report used Cre/Lox inducible disruption of exon 5 to show that myeloid differentiation in adult mice was not affected by loss of Runx1 expression (Ichikawa et al., 2004) . Normal myeloid development in the absence of Runx1 expression is not consistent with lineage progression being the primary role of Runx1 in suppression of myeloid leukemia.
Several studies have indicated that Runx1 activity may extend beyond regulation of cell differentiation. Runx1-ETO expression in mice resulted in the presence of hematopoietic progenitors that showed aberrant proliferation in vitro with an increased capacity for self-renewal (Okuda et al., 1998) . Similar results were obtained from ectopic expression of Runx1-ETO in hematopoietic stem and progenitor cells using retroviral transduction. Runx1-ETO expression caused a strong enhancement in self-renewal of hematopoietic stem cells but inhibited colony formation by committed progenitors in response to cytokine treatment (Mulloy et al., 2002) .
Part of the reason why studies of Runx1-associated leukemogenesis have focused on its role in differentiation is that the protein is a transcriptional regulator of known differentiation associated genes. For example, Runx1 may control macrophage development by regulating CSF-1 receptor (CSF-1R) expression (Zhang et al., 1996a) . CSF-1 (also termed macrophage-CSF) is required for macrophage development as determined by the phenotype of mice with a targeted deletion of the CSF-1R or a natural mutation in the CSF-1 gene (Cecchini et al., 1997; Dai et al., 2002) . Previous work showed that Runx1 can synergistically activate the human c-fms (CSF-1R) gene promoter with PU.1 and C/EBP proteins (Zhang et al., 1996a; Petrovick et al., 1998) . The binding site in the human c-fms promoter, however, is not conserved between human and mouse. In this report, we characterize multiple binding sites within the human and mouse genes and demonstrate that Runx1 is also an important regulator of the mouse c-fms gene.
Although c-fms gene expression is a differentiation marker for the macrophage lineage (Tagoh et al., 2002; Sasmono et al., 2003) , signaling from CSF-1 receptor encoded by this gene is also involved in macrophage survival and proliferation. Removal of CSF-1 from macrophage cultures leads to cessation of proliferation, and eventually to programmed cell death. An early event in this pathway is rapid upregulation of the CSF-1 receptor. We report here that expression of the Runx1 transcription factor is itself acutely regulated by CSF-1 and may contribute to both CSF-1 receptor upregulation and the control of cell survival and proliferation at later stages of macrophage development. We further show that ectopic Runx1 expression resulted in growth arrest of macrophage-like and early myeloid progenitor cell lines. Our data suggest a dual role for Runx1 as an important factor for macrophage development through CSF-1R expression and as an inhibitor of cell proliferation or survival by restricting cytokine-independent proliferation.
Results

Runx1 activates expression of the mouse CSF-1R gene
Runx1 has been shown to trans-activate the human c-fms gene proximal promoter, but the core consensus Runx1 binding site is not conserved in the mouse c-fms gene promoter. Furthermore, the appropriate expression of the c-fms gene actually requires a contribution from a highly conserved intronic enhancer, termed the Fms intronic regulatory element (FIRE) (Himes et al., 2001) , which has additional potential Runx1 binding sites (Tagoh et al., 2002; Follows et al., 2003) . Since CSF-1R is similarly expressed in human and mouse macrophages, we anticipated that the key control mechanisms would also be conserved across species. We therefore carried out experiments to determine whether Runx1 regulates expression of the mouse gene and to determine whether activation involves putative conserved binding sites in the FIRE enahncer. Towards this end, we produced expression constructs for both full-length Runx1 (PEBP2aB) and CBFb proteins based on the pEF6 expression plasmid that uses the EF-1a promoter for stable expression of genes. Stable transfection of the macrophage-like RAW264.7 cell line with either the pEFRunx1 or pEFCBFb expression constructs was performed and cells were analysed for CSF-1R expression by antibody staining and flow cytometry. The level of CSF-1R expression in RAW264.7 cells was low, but increased significantly with expression of either Runx1 or CBFb. Runx1 expression alone resulted in a greater than 10-fold increase in surface expression of CSF-1R when compared to the empty vector (pEF6) control (Figure 1) . Expression of the CBFb cofactor also enhanced CSF-1R expression but to a lesser extent than Runx1. This finding represents the first direct evidence that expression of the CSF-1R gene product, as opposed to promoter activity, can be controlled by Runx1.
Mouse and human c-fms genes contain multiple CBF binding sites Sequence analysis of regulatory regions revealed that the location of CBF binding sites within the mouse and human c-fms genes may not be conserved (Himes et al., 2001) . Electrophoretic mobility shift assays (EMSA) were used to identify binding sites in either the promoter or enhancer of the mouse and human genes. Specific antibody to the Runx1 protein was used to identify Runx1 containing protein complexes by antibody supershift. This analysis showed that both the human and mouse genes contain two sites that bind CBF proteins with high affinity. In the mouse gene, both CBF binding sites were present in the enhancer. There was an upstream site whose sequence showed no conservation with the human gene enhancer by alignment (MRxE) and a second downstream element which was completely conserved (HMRxE) (Figure 2a ). The sequence within the mouse promoter that corresponds to the previously characterized human element contains a single base change from the TGTGGT core consensus and showed weak CBF protein binding (MRxP). In the human gene, the sites are separated, one in the promoter and the conserved site in the enhancer (HRxP and HMRxE). All sites bound multiple protein complexes, which can be supershifted with Runx1 antibody (Figure 2b ).
The relative affinity of Runx1 binding sites was determined by ability to compete for CBF binding to a consensus site in the Molony Leukemia Virus LTR, PEBP2a (Satake et al., 1992) . Unlabeled oligonucleotide from each of the c-fms binding sites was added to the binding reaction at a ratio of 20 : 1 with the labeled PEBP2a probe. The results showed that the G to A substitution in the core consensus sequence (TGTGGT), seen in the mouse c-fms gene promoter, significantly reduced the affinity for CBF. The consensus elements in the human c-fms promoter site and the site in the mouse enhancer that is not conserved in the human enhancer both showed a strong affinity for CBF with nearly complete competition for CBF binding with the PEBP2a probe. The conserved site in the enhancer that shows a T to G substitution (HMRxE) in the final base of the core consensus sequence was also able to compete for CBF binding, but was less effective compared to the consensus elements (Figure 2c ).
Runx1 trans-activates the mouse CSF-1R promoter through the intronic enhancer
Luciferase reporter constructs were used to determine whether Runx1 can function at the level of transcription through either promoter or enhancer elements of the mouse c-fms gene. We also wished to determine if Runx1 expression would alter the position dependence of FIRE enhancer activity. Our previous work showed that the intronic enhancer of the c-fms gene was highly active when inserted proximal to the c-fms gene promoter and insertion distal to the promoter, downstream of the luciferase coding region, resulted in substantial loss of enhancer activity in RAW264.7 cells (Himes et al., 2001 ). This speculation was based on the fact that the CBF protein complex is capable of interacting with numerous transcription factors and cofactors, including the PU.1 protein which can bind sites in both the human and mouse promoters (Petrovick et al., 1998) . These results have suggested that CBF proteins may act as organizing factors, allowing the recruitment of proteins that bind distal elements into the transcription complex.
Consistent with the lack of high-affinity binding sites, CBF proteins were capable of only weak trans-activation of the mouse c-fms gene proximal promoter alone. In RAW264.7 cells, the presence of the enhancer permitted a significant increase in CBF activation whether the enhancer was located proximal (p0.5fmsUE) or distal (p0.5fmsDE) to the promoter. The constitutive activity of the two enhancer constructs varied considerably. The p0.5fmsUE reporter construct showed strong enhancer activity even in the absence of Runx1/CBFb expression resulting in a six fold increase in expression through the c-fms gene promoter. The p0.5fmsDE construct required CBF co-transfection for high-level enhancer activity. In the absence of CBF expression, the distal enhancer produced a less than twofold increase in reporter gene activity. Expression of CBF proteins resulted in a significant increase in enhancer activity, resulting in an over five-fold increase in reporter expression over the promoter alone (Figure 3 ). The position of the enhancer in p0.5fmsDE, downstream from the start of transcription, more closely mimics positioning within the endogenous CSF-1R gene. Low-level expression in the absence of CBF protein expression was also consistent with the expression pattern of the CSF-1R gene in RAW264.7 cells (Figure 1 ).
Runx1 expression is induced upon removal of CSF-1 from macrophages
Surface CSF-1R, and c-fms mRNA expression is relatively low in macrophages exposed to saturating amounts of CSF-1, and is inducible upon CSF-1 removal (Hume et al., 1997) . The mechanism of this feedback loop has not previously been identified. Since Runx1 is a potent trans-activator of the c-fms gene, we analysed the effect of CSF-1 removal on expression of Runx1 mRNA. Bone marrow-derived macrophages (BMM), which are dependent upon CSF-1 for proliferation and survival, were either maintained in CSF-1, or depleted of CSF-1 for 16 h, and the level of Runx1 mRNA was measured by real-time RT-PCR analysis. Runx1 expression increased 4.3-fold when BMM were deprived of CSF-1 for 16 h. Subsequent treatment of starved BMM with CSF-1 resulted in a rapid decline in Runx1 expression after 4 h of treatment with a greater than 80% decrease in expression compared to CSF-1 deprived cells (Figure 4a, b) . Western blot analysis was used to determine the level of Runx1 protein expression in cell lines and proliferating or quiescent BMM. CSF-1-stimulated BMM showed a low-level expression of Runx1 protein that increased significantly when BMM were deprived of CSF-1 (Figure 4c ). For comparison, the level of Runx1 expression in starved BMM was found to be significantly higher than in the growth factor-independent mouse RAW264.7 macrophage line, or in the human mono-mac-6 pro-monocytic cell line.
Inhibition of cell proliferation by Runx1
The reversible induction of runx1 following growth factor deprivation in BMM suggests that runx1 may act as a growth or survival inhibitor in myeloid cells in addition to its action on CSF-1R expression. We had previously noted that attempts to achieve stable overexpression of Runx1 in RAW264.7 cells were unsuccessful, and were associated with a substantial reduction in the number of primary transformants (colonies) compared to empty vector controls. To quantitate this phenomenon, cell viability assays (based upon MTT dye reduction assay; see Materials and methods) were performed immediately after antibiotic selection to evaluate the effect of ectopic expression on the growth and viability of transfected cell lines. Runx1-expressing cells showed a 72% decrease in viable cells and CBFbexpressing cells a 41% decrease compared to nonexpressing cells transfected with the empty vector, pEF6.
Since RAW264.7 cells are a mouse line, and transformed with the v-abl oncogene, we wished to 
Runx1 acts as a growth inhibitor but not a differentiation factor in EM-3 cells
Inhibition of cell proliferation or viability by expression of Runx1 could be explained by changes in the differentiation state of cells. Although both the RAW264.7 and Mono-Mac-6 cell lines display macrophage-like properties and are positive for most monocyte/macrophage cell markers, Runx1-mediated repression of growth or survival may still result from terminal differentiation of cells. EM-3 cells expressed Runx1 and showed reduced toxicity with ectopic expression of Runx1 compared to the pro-monocytic cell lines. EM-3 cells appear to be early progenitors and are negative for most myeloid cell surface markers except the CD13 and CD15 myeloid cell surface markers (German Tissue Culture Collection, DMSZ). Unlike RAW264.7 or Mono-Mac-6 cells, ectopic expression in EM-3 cells did not result in significant changes in cell morphology or the ability of cells to adhere to tissue culture plastic (data not shown). The data are also consistent with no change in myeloid development with inducible knockout of Runx1 (Ichikawa et al., 2004) . A more detailed analysis of cell cycle and cell death using propidium iodide was performed on transfected EM-3 cells since significant numbers of cells could be obtained after antibiotic selection. EM-3 cells overexpressing Runx1 showed a 9.5-fold increase in the rate of cells undergoing apoptosis, as defined by cells containing less than 2N DNA, and a 36% decrease in the number of cells in cycle. In contrast, expression of CBFb resulted in relatively minor effects on growth or survival (Figure 6a, b, c) . The level of expression of either Runx1 or CBFb protein was determined in three independent stable transfection pools by Western blot analysis of V5 epitope tagged protein. The level of protein expression was similar indicating that changes in growth and survival were not due to significant differences in the level of either Runx1 or CBFb protein expression. The level of expression of the developmental transcription factor PU.1 was also determined since this protein is critical for myeloid development. 
Discussion
Control of CSF-1 receptor expression is critical for normal regulation of macrophage differentiation, proliferation and survival. When macrophages are deprived of CSF-1, they respond by increasing transcription of c-fms mRNA resulting in enhanced expression of CSF-1 receptor on the cell surface. If there is a progressive loss of receptor signaling, cells will undergo programmed cell death. The data presented here extend previous studies by showing that Runx1 is both a critical regulator of c-fms gene expression and a member of a novel class of genes that is specifically induced following growth factor deprivation.
We have shown previously that interactions between the FIRE downstream enhancer within intron 2 and the promoter were required for c-fms gene expression in macrophages (Himes et al., 2001) . Previous studies on the function of Runx1/AML in humans have focused solely on the promoter (Zhang et al., 1996a) , although recently Follows et al. (2003) confirmed that putative runx1/AML1 sites within FIRE are occupied in both mouse and human genes. CBF proteins function through their ability to bind multiple families of transcription factors and transcriptional cofactors. The postulated role of the CBF protein complex as an organizing factor was supported by the highest level of Runx1/CBFb induction occurring when the enhancer was located distal to the promoter (Figure 3) . This observation may, in part, explain the lack of conservation in the position of CBF binding sites in the promoters and enhancers of the mouse and human genes.
Runx1 expression in mature macrophages showed an inverse correlation to the level of cell proliferation and survival. Removal of CSF-1 results in a rapid cell cycle arrest and a substantial rise in the rate of cell death. The corresponding increase in the level of Runx1 protein could lead to expression of genes that control both cellular proliferation and survival. This possibility is supported by the ability of Runx1 to trans-activate expression of p14ARF, a potent tumor suppressor that can activate p53 by inactivating Mdm2 (Linggi et al., 2002) . Runx1 expression in response to growth factor withdrawal may, in part, act by raising the level of p14ARF. Expression of the CBFb-SMMC translocation product in p16(INK4A)/p19ARF(À/À) mice resulted in increased development of acute leukemia suggesting that Runx1 regulates additional tumor suppressor genes to p14ARF (Yang et al., 2002) .
The resistance of EM-3 cells and sensitivity of promonocytic cell lines to ectopic expression of Runx1 was consistent with distinct regulation at late stages of macrophage development. CML is a malignant disorder of hematopoietic stem cells characterized by a preferential expansion of myeloid cells resulting in high blood counts and splenomegaly (Sawyers, 1999) . Runx1 is normally expressed in hematopoietic progenitor cells that are capable of self-renewal. As previously discussed, Runx1 plays a clear role in suppression of growth during lineage progression. Our data showing stable expression of Runx1 increased the number of EM-3 cells in G 1 /G 0 is consistent with an ability to inhibit cell cycle progression. Although both loss of Runx1 and expression of Runx1-ETO enhance self-renewal of progenitors, Runx1-ETO expression has a distinct effect on myeloid cell differentiation, suppressing colony formation in response to cytokine treatment (Okuda et al., 1998; Mulloy et al., 2002) . Our results are consistent with these findings in that Runx1 activated an enhancer of cfms gene expression but was not required for minimal expression through the promoter. The RAW264.7 cells expressed CSF-1 receptor at low levels despite undetectable levels of Runx1 expression. The ETO histone deacetylase activity in the fusion protein must then act to dominantly suppress promoter trans-activation in mice expressing Runx1-ETO.
A second family member, Runx3, has similar tumor suppressor properties to Runx1. Loss of Runx3 function is causally related to progression of gastric cancer in mice and humans (Li et al., 2002) . Consistent with our Runx1 expression studies, ectopic expression of Runx3 in gastric cancer cell lines resulted in inhibition of cell growth (Fukamachi and Ito, 2004 ). Runx1 and Runx3 bind similar sequences and both form protein complexes with the cofactor CBFb; hence, both proteins may inhibit growth by activating expression of common tumor suppressor genes (Levanon et al., 2003) . Runx3 mRNA was also detectable in mature macrophages (data not shown) and this expression may be involved in the ability of CBFb expression alone to effect cell growth and survival. Identification of genes whose expression can be activated by either Runx1 or Runx3 could provide an insight into the reduced capacity for self-renewal during myeloid lineage progression.
The data presented here and by others suggest that CBF transcription factors function as an important link between cell differentiation and proliferation or survival. Runx1 may then regulate genes that both promote differentiation of progenitor cells and reduce their capacity for self-renewal. CSF-1 receptor levels increase as myeloid cells differentiate to macrophages and Runx1 may be an important inhibitor of cytokineindependent growth or survival in mature macrophages. High-level expression in mature macrophages may then provide a terminal differentiation signal that blocks cell proliferation.
Materials and methods
Cell culture and transfection
Bone marrow cells were isolated from the femurs of adult C57/ black 6 mice and cultured in RPMI media containing penicillin-streptomycin antibiotics (Gibco/Invitrogen). Cells were differentiated to macrophages by a 5-day treatment with 1000 units of human CSF-1 (Chiron Corp., Emeryville, CA, USA). RAW264.7, Mono-Mac-6 (ATCC) and EM-3 cells (DSMZ) were cultured in RPMI medium as described above.
The pGL0.5fms, pGL0.5fmsDE and pGL0.5fmsUE plasmids have all been previously described (Himes et al., 2001) . The pEFRunx1 and pEFCBFb plasmids were made by RT-PCR amplification from mRNA using specific primers for insertion into the pEF6 vector in frame with a C-terminal V5/His tag (Invitrogen). The integrity of the coding region was confirmed by DNA sequencing and protein expression verified by Western blot of V5 tagged recombinant protein in cell lysates after transient transfection. Stable transfections were performed by electroporation of 5 Â 10 6 cells in 400 ml RPMI media containing 20 mM HEPES and 10 mg of expression plasmid at 280 V and 1000 mF capacitance on a Bio Rad Gene Pulser (Bio Rad), followed by selection with 1 mg/ml Blastocidin. Transient transfections were performed as above with 5 mg of reporter plasmid and 10 mg of expression plasmid. All reporter transfections were performed using a common pool of cells since no significant changes in transfection efficiency were observed when measured using a CMVGFP expression plasmid in parallel transfections and flow cytometry. As in previous studies (Himes et al., 2001) . we have chosen not to use an internal reference promoter because changes in reference promoter activity can alter the test promoter through promoter competition. Cells were lysed 36 h post-transfection and assayed for luciferase activity according to the manufacturer's protocol (Roche Biochemical). The concentration of protein was determined by BCA protein assay (Pierce) and the level of luciferase activity was given as relative light units (RLU), calculated as light units/mg of protein assayed.
Electrophoretic mobility shift assay
Isolation of nuclei and extraction of protein from BMM was performed according to established protocols and the concentration of protein in nuclear extracts was determined by BCA protein assay (Pierce). The double-stranded oligonucleotide probes used contained the following sequences: HRxP, CCAAACTCTGTGGTTGCCTT; MRxP, CCAAATTCTG TAGTTCCCTT; MRxE, GCTGACACCACACAGGCAAC GA; HMRxE, TTTCCGCCCACACAGGCCG; PEBP2, GGATATCTGTGGTAAGCA. Binding reactions contained 20 mM HEPES buffer pH 7.4, 40 mM NaCl, 15% glycerol, 1 mg of protein from nuclear extract, 25 ng poly(dI-dC) and approximately 0.01 pmol of 32 P-labelled probe for 20 min at room temperature. Antibody supershifts were performed by preincubating binding reactions with antibody to Runx1 (Santa Cruz Biotechnology) for 15 min at 41C before addition of probe and protein binding. Competitions were performed by addition of unlabelled oligonucleotide immediately before addition of labelled probe. Protein binding was resolved on 5% mini-polyacrylamide gels (Bio Rad) in 0.5XTBE (45 mM Tris base, 45 mM boric acid and 1 mM EDTA) for 1 h at 100 V.
Analysis of cell cycle and apoptosis
For MTT assays, 1 Â 10 4 transfected cells/well (viable by trypan blue exclusion) were seeded into 96-well plates and cultured for 48 h before treatment with 1 mg/ml MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) in 50 ml of media for 1 h. Cells were then treated with isopropyl alcohol and absorbance at 595 nM measured. For cell cycle analysis, 2 Â 10 6 transfected EM-3 cells were cultured in 25 cm 2 flasks for 24 h in fresh media before harvesting and fixation in 70% ethanol. Fixed cells were stained with propidium iodide according to established protocols. Cells were analysed for propidium iodide fluorescence on a Facstar flow cytometer (Becton Dickinson).
Western blot and immunofluorescent stain
Protein from nuclear extracts was desalted on microcon columns and 5 mg of protein denatured for resolution on precast 12% polyacrylamide gels (Invitrogen) before blotting onto PVDF membrane. Blots were stained with specific antibody to Runx1, PU.1 (Santa Cruz Biotechnology) or V5 epitope (Cell Signalling) and bands visualized using a horseradish peroxidase conjugated antibody to goat IgG (Pierce), rabbit IgG or mouse IgG (Cell Signalling) and chemiluminescence substrate (Amersham). Cell surface expression of CSF-1 receptor was measured by indirect immunofluorescence. Cells were stained with CSF-1R-specific monoclonal antibody (Sudo et al., 1995) or isotype control (Cochet et al., 1998) followed by a FITC labelled conjugate antibody (Serotec) and fluorescence levels measured by flow cytometry.
RNA isolation and quantitative PCR
Total RNA was prepared using RNeasy isolation kits (Qiagen) according to the manufacturer's instructions. RNA was treated with DNase 1 (Ambion) and reverse transcribed to cDNA using Superscript reverse transcriptase (Life Technologies). Negative control samples (no first strand synthesis) were prepared by performing reverse transcription reactions in the absence of reverse transcriptase. cDNA levels of murine hypoxanthine phosphoribosyl transferase (HPRT), Runx1 and CSF-1R were quantitated by SYBR green, real-time PCR using an ABI Prism 7700 sequence detector (Applied Biosystems) according to the manufacturer's instructions. Amplification was achieved using an initial cycle of 501C for 2 min and 951C for 10 min, followed by 40 cycles of 951C for 15 s and 501C for 1 min. Specificity of PCR was checked by gel electrophoresis and melting curve analysis. cDNA levels during the linear phase of amplification were normalized against HPRT controls. Determinations were made in triplicate and mean7s.d. was determined. Real-time primers (f, forward; r, reverse) used to detect expression of the corresponding murine genes were as follows: Runx1: f, 5 0 -CA CCGACAGCCCCAACT-3 0 ; r, 5 0 -CCCCAGTGCCACCACCT-3 0 ; CSF-1R: f, 5 0 -TACCACCATCCACTTGTATGT-3 0 , r, 5 0 -TG TCCTCCACTGTCACCAACTC-3 0 ; HPRT: f, 5 0 -GCAGTA CAGCCCCAAAATGG-3 0 ; r, 5 0 -AACAAAGTCTGGCCTG TATCCAA-3 0 .
